Telegraph Hill Partners
VC Fund
San Francisco, United States
Telegraph Hill Partners is a venture capital firm that invests behind technology leaders in the life science, medical devices, and healthcare industries. THP was founded in 2001 by J. Matthew Mackowski, Robert Shepler, Dr. Thomas Raffin, and Deval Lashkari, and is headquartered in San Francisco, California.
- Total investments:
- 52
- Last investment:
- Lead investor:
- 71%
- Fund size:
- $525M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Telegraph Hill Partners invests in
Stages Telegraph Hill Partners invests in
Countries Telegraph Hill Partners invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Alexander C. Herzick
|
|||
Deval A. Lashkari
|
|||
Jeanette M. Welsh
|
|||
Rob C. Hart
|
|||
Thomas A. Raffin
|
|||
| See all 9 contacts → | |||
Investment Focus
Industry
- Biotechnology 19 (37%)
- Health Care 18 (35%)
- Medical 9 (17%)
- Medical Device 8 (15%)
- Life Science 6 (12%)
Stage
- Funding Round 13 (25%)
- Series A 8 (15%)
- Series B 7 (13%)
- Venture - Series Unknown 5 (10%)
- Series C 3 (6%)
Country
- United States 28 (54%)
- Canada 1 (2%)
- United Kingdom 1 (2%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Alexander C. Herzick
Partner
|
Partner | Total investments: 6 | Find email | |
|
Deval A. Lashkari
Senior Partner
|
Senior Partner | Total investments: 5 | Find email | |
|
Jeanette M. Welsh
Partner
|
Partner | Total investments: 1 | Find email | |
|
Rob C. Hart
Partner
|
Partner | Total investments: 4 | Find email | |
|
Thomas A. Raffin
Senior Partner/Co-Founder,
|
Senior Partner/Co-Founder, | Total investments: 9 | Find email | |
| See all 9 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
etherFAX
|
etherFAX they digitize workflows and optimize business processes. They provide hybrid-cloud fax solutions supporting healthcare enterprises, documents directly to applications and devices . | Venture - Series Unknown / Jun 16, 2026 | |
Kytopen
|
Kytopen develops genome engineering platforms that enable cell therapy research and manufacturing. The company provides non-viral gene delivery systems that facilitate the delivery of mRNA, DNA, and CRISPR Cas9 RNP into cells while retaining cell functionality. Its Flowfect® technology allows high-throughput transfections and scalable optimizationfrom small experiments to large-scale manufacturing.Kytopen’s platforms include Flowfect Discover™ for automated small-volume screening and Flowfect TX® for large-scale delivery, supporting drug discovery and process development. The systems integrate electrical, mechanical, and chemical forces to fine-tune gene delivery, enabling controlled and predictable scaling. The company’s solutions focus on removing bottlenecks in gene delivery and streamlining the transition from laboratory research to therapeutic production. | Series B / Apr 07, 2026 | |
Promptly
|
Promptly is a web-based patient experience and automation suite designed for medical practices. | Series A / Jun 27, 2024 | |
Argonaut Manufacturing Services
|
Argonaut provides contract manufacturing for biopharmaceutical, diagnostics and life science organizations. The company's services include high-yield aseptic fill/finish, reagent formulation, filling, kitting, lyophilization, and analytical support. It provides a wide range of diagnostics and drug products for diverse outsourcing needs. | $45M / Series A / Mar 05, 2024 | |
Cell Microsystems
|
Cell Microsystems is an early growth stage company that develops, manufactures, and markets innovative products for single-cell biology. The company’s proprietary CellRaft™ Technology enables high-efficiency sorting and isolation of single cells under standard culture conditions resulting in unperturbed phenotypes and high viability. Coupled withthe company’s automated imaging platform, a user can select a cell in real-time and ‘track and trace’ that cell through imaging, collection, and downstream analysis. By sorting during real-time imaging, no cells are wasted enabling single-cell isolation from even small, precious samples. The CellRaft Technology offers scalable solutions making cell separation technology available for every lab. | $6.5M / Series B / Aug 23, 2023 | |
Panome Bio
|
Panome Bio is a biomarker discovery platform offering biomarker analysis. The company's services also include metabolomics, lipidomics, and proteomics screening solutions through untargeted analysis and proprietary computational methods. Panome Bio was founded in 2022 and is headquartered in Saint Louis, Missouri. | $6M / Series A / Feb 24, 2023 | |
|
Panome Bio
|
Panome Bio is a biomarker discovery platform offering biomarker analysis. The company's services also include metabolomics, lipidomics, and proteomics screening solutions through untargeted analysis and proprietary computational methods. Panome Bio was founded in 2022 and is headquartered in Saint Louis, Missouri. | $6M / Series A / Feb 24, 2023 | |
|
Panome Bio
|
Panome Bio is a biomarker discovery platform offering biomarker analysis. The company's services also include metabolomics, lipidomics, and proteomics screening solutions through untargeted analysis and proprietary computational methods. Panome Bio was founded in 2022 and is headquartered in Saint Louis, Missouri. | $6M / Series A / Feb 24, 2023 | |
|
Argonaut Manufacturing Services
|
Argonaut provides contract manufacturing for biopharmaceutical, diagnostics and life science organizations. The company's services include high-yield aseptic fill/finish, reagent formulation, filling, kitting, lyophilization, and analytical support. It provides a wide range of diagnostics and drug products for diverse outsourcing needs. | Jan 10, 2023 | |
Emerging Therapy Solutions
|
Emerging Therapy Solutions is an insurance company that specializes in the full management of gene and cell therapy for payers. It focuses on the development of proprietary targeting and segmentation algorithms to break down rare conditions. The company was founded in 2018 and headquartered in Minneapolis, Minnesota. | $3M / Venture - Series Unknown / Dec 20, 2022 | |
| See all 52 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Telegraph Hill Partners invest in?
Telegraph Hill Partners invests primarily in Biotechnology, Health Care and Medical startups, most often at Funding Round and Series A stage. Most of the 52 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Telegraph Hill Partners?
Public channels for Telegraph Hill Partners include LinkedIn, the website linked on this profile and Facebook. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Telegraph Hill Partners?
The team at Telegraph Hill Partners includes Alexander C. Herzick (Partner), Deval A. Lashkari (Senior Partner) and Jeanette M. Welsh (Partner), among 9 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
